These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 9559820

  • 1. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones.
    Zhao X, Wang JY, Xu C, Dong Y, Zhou J, Domagala J, Drlica K.
    Antimicrob Agents Chemother; 1998 Apr; 42(4):956-8. PubMed ID: 9559820
    [Abstract] [Full Text] [Related]

  • 2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 3. Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.
    Takei M, Fukuda H, Kishii R, Kadowaki Y, Atobe Y, Hosaka M.
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3337-8. PubMed ID: 12234876
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.
    Tanaka M, Onodera Y, Uchida Y, Sato K.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3044-6. PubMed ID: 9797253
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY, Trucksis M, Hooper DC.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F.
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [Abstract] [Full Text] [Related]

  • 14. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
    Lu T, Zhao X, Drlica K.
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC.
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [Abstract] [Full Text] [Related]

  • 19. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.
    Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya S.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1835-42. PubMed ID: 8843290
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.